2012•Drug Evaluation ResearchRequires access

Advances in studies on Rotigotine transdermal patch

Xuewen Han

Abstract

Rotigotine transdermal patch is the first transdermal non-ergot dopamine agonist,which is a selective dopamine D1/D2/D3 receptor agonist.Rotigotine patch is effective over 24 h providing a continuous dopaminergic stimulation in patients with Parkinson's disease(PD) and is approved for use in treatment of PD by the FDA and EMA.This paper is a review of current status of Rotigotine transdermal patch.

About this research paper

What this paper is about

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Rotigotine, Transdermal patch, Transdermal, Dopamine agonist, Agonist, Dopaminergic, Medicine, Pharmacology